The aim of this study was to analyze the expression of NER and HR genes (i.e., ERCC1, ERCC5, and BRCA1), as well as CUL4A, as potential predictive factors of trabectedin efficacy in STS. The gene discussed is CUL4A; the disease is telomere syndrome.